Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat

Journal of Neurochemistry

Volumn 80, Issue 3, 2002, Pages 365-374

  Barc, Stéphanie ^a,b   Page, Guylène ^a   Barrier, Laurence ^a,b   Garreau, Lucette ^c   Guilloteau, Denis ^c   Fauconneau, Bernard ^a,b   Chalon, Sylvie ^c  

^a GEMCI   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Biodistribution; MPP+ rat model; PE2I; Striatal markers; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4' METHYLPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; BRAIN SLICE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; MALE; NERVE CELL LESION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL MARKERS; CELL MEMBRANE; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MPTP POISONING; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NORTROPANES; ORGAN CULTURE TECHNIQUES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYNAPTOSOMES; TRITIUM; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA;

EID: 0036488136     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-3042.2001.00743.x     Document Type: Article

References (58)

1. +): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. Eur. J. Pharmacol. 131, 199-209.
2. Annepu J. and Ravindranath V. (2000) 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain. Neurosci. Lett. 289, 209-212.
3. +. Brain Res. (in press).
4. Bezard E., Imbert C., Deloire X., Bioulac B. and Gross C. (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766, 107-112.
5. 3H]-GBR 12783 specific binding during the maturation of rat striatum. Life Sci. 44, 1759-1765.
6. + injection into rat substantia nigra causes secondary glial activation but not cell death in the ipsilateral striatum. Neurobiol. Dis. 7, 343-361.
7. Chalon S., Emond P., Bodard S., Vilar M. P., Thiercelin C., Besnard J. C. and Guilloteau D. (1999a) Time course of changes in striatal dopamine transporters and D2 receptors with specific ionidated markers in a rat model of Parkinson's disease. Synapse 31, 134-139.
8. Chalon S., Garreau L., Emond P., Zimmer L., Vilar M. P., Besnard J. C. and Guilloteau D. (1999b) Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′- methylphenyl) nortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J. Pharm. Exp. Ther 291, 648-654.
9. Chiueh C. C., Markey S. P., Bums R. S., Johannessen J. N., Pert A. and Kopin I. J. (1984) Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol. 100, 189-194.
10. Daniels G. M. and Amara S. G. (1999) Regulated trafficking of the human dopamine transporter. J. Biol. Chem. 274, 35794-35801.
11. Dentresangle C., Le Cavorsin M., Savasta M. and Leviel V. (2001) Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substancia nigra. Brain Res. 893, 178-185.
12. Desole M. S., Esposito G., Fresu L., Migheli R., Sircana S., Delogu R., Mièle M. and Mièle E. (1996) Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat. Pharmacol. Biochem. Behav. 54, 377-383.
13. Emond P., Garreau L., Chalon S., Boazi M., Caillet M., Bricard J., Frangin Y., Mauclaire L., Besnard J. C. and Guilloteau D. (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′-iodophenyl) nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(3′,4′- disubstituted phenyl) nortropane. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem. 40, 1366-1372.
14. Fornai F., Battaglia G., Gesi M., Giorgi F. S., Orzi F., Nicoletti F. and Ruggieri S. (2000) Time course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res. 887, 110-117.
15. Frey K. A., Koeppe R. A., Kilbourn M. R., Vander Borght T. M., Albin R. L., Gilman S. and Kulh D. E. (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40, 873-884.
16. Gerlach M. and Riederer P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103, 987-1041.
17. Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
18. Glowinski J. and Iversen L. L. (1966) Regional studies of catecholamines in rat brain. J. Neurochem. 13, 655-663.
19. Goulet M., Morissette M., Grondin R., Falardeau P., Bedard P. J., Rostene W. and Di Paolo T. (1999) Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse 32, 153-164.
20. Graybiel A. M., Moratalla R., Quinn B., De Lanney L. E., Irwin I. and Langston J. W. (1993) Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys. Adv. Neurol. 60, 34-39.
21. Guilloteau D., Emond P., Baulieu J. L., Garreu L., Frangin Y., Pourcelot L., Mauclaire L., Besnard J. C. and Chalon S. (1998) Exploration of the dopamine transporter: in vitro and in vivo characterization of 22 a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′- methylphenyl) nortropane (PE2I). Nucl. Med Biol. 25, 331-337.
22. 125I]PE2I. Neuroimage 9, 108-116.
23. Harik S. I., Schmidley J. W., Iacofano L. A., Blue P., Arora P. K. and Sayre L. M. (1987) On the mechanisms underlying 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. J. Pharm. Exp. Ther. 241, 669-676.
24. +) to rats. Neurosci. Lett. 59, 135-140.
25. Heikkila R. E., Sieber B. A., Manzino L. and Sonsalla P. K. (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-terahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol. 10, 171-183.
26. Hogan K. A., Staal R. G. W. and Sonsalla P. K. (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74, 2217-2220.
27. 3H-dopamine into synaptosomes from rat striatum. Mol. Pharmacol. 10, 746-758.
28. Jakson-Lewis V., Jacowee M., Burke R. E. and Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. Neurodegeneration 4, 257-269.
29. Kilbourn M. R. (1997) In vivo radiotracers for vesicular neurotransmitter transporters. Nucl. Med. Biol. 24, 615-619 .
30. Kilbourn M. R., Kuszpit K. and Sherman P. (2000) Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35, 250-255.
31. Kopin I. J. and Markey S. P. (1988) MPTP toxicity: implication for research in Parkinson's disease. Annu. Rev. Neurosci. 11, 81-96.
32. Kuikka J. T., Baulieu J. L., Hiltunen J., Halldin C., Bergstrom K. A., Farde L., Emond P., Chalon S. YuM., Nikula T., Laitinen T., Karhu J., Tupala E., Hallikainen T., Kolehmainen V., Mauclaire L., Maziere B., Tiihonen J. and Guilloteau D. (1998) Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur. J. Nucl. Med. 25, 531-534.
33. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. J. (1983) Chronic parkinsonism in human due to a product of meperidine analog synthesis. Sci. 219, 979-980.
34. Lesch K. P. and Bengel D. (1995) Neurotransmitter reuptake mechanisms. Pharmacol. Pathophysiol. CNS Drugs 4, 302-322.
35. 3H]PTT), for dopamine transport sites in rat brain. J. Pharmacol. Exp. Ther. 293, 686-696.
36. Mandavilli B. S., Ali S. F. and Van Houten B. (2000) DNA damage in brain mitochondria caused by aging and MPTP treatment. Brain Res. 885, 45-52.
37. Masson J., Sagne C., Hamon M. and El Mestikawy S. (1999) Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439-464.
38. Masuo Y., Montagne M. N., Pelaprat D., Scherman D. and Rostene W. (1990) Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density. Brain Res. 520, 6-13.
39. +. J. Neurochem. 73, 750-757.
40. Mizuno Y., Saitoh T. and Sone N. (1987) Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4phenyl-pyridinium ion. Biochem. Biophys. Res. Commun. 143, 294-299.
41. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T. and Kagawa Y. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455.
42. + cause nigrostriatal toxicity after substantia nigra injections in rats. Brain Res. 675, 279-288.
43. Nicklas W. J., Vyas I. and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
44. Opacka-Juffry J., Ashworth S., Hume S. P., Martin D., Brooks D. J. and Blunt S. B. (1995) GDNF protects against 6-OHDA nigrostriatal lesion: in vivo with microdialysis and PET. Neuroreport 7, 348-352.
45. Paxinos G. and Watson C. (1999) The Rat Brain in Stereotaxic Coordinates. Academic Press, New-York.
46. Pérez-Otaño I., Oset C., Luquin M. R., Herrero M. T., Obeso J. A. and Del Rio J. (1994) MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci. Lett. 175, 121-125.
47. Peterson G. L. (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83, 346-356.
48. Pope-Coleman A., Tinker J. P. and Schneider J. S. (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 36, 120-128.
49. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L. and Dawson T. M. (1996) Role of nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. 93, 4565-4571.
50. 3H]GBR 12935: binding characteristics. Brain Res. 540, 1-13.
51. Schapira A. H. V., Holt I. J., Sweeney M., Harding A. E., Jenner P. and Marsden C. D. (1990) Mitochondrial DNA analysis in Parkinson's disease. Mov. Disord. 5, 294-297.
52. Schwarting R. K. and Huston J. P. (1996) The unilateral 6-hydroxy-dopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
53. Sershen H., Reith M. E. A., Hashim A. and Lajtha A. (1984) Reduction of dopamine uptake and cocaïne binding in mouse striatum by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur. J. Pharmacol. 102, 175-178.
54. +. J. Neural. Transm. 74, 75-86.
55. Takada M., Matsumura M., Kojima J., Yamaji Y., Inase M., Tokuno H., Nambu A. and Imai H. (2000) Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur. J. Neurosci. 12, 1771-1780.
56. Tatton N. A. and Kish S. J. (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-treated mice using terminal deoxynucleotidyl transferase labeling and acridine orange staining. Neurosci. 77, 1037-1048.
57. Wilson J. M. and Kish S. J. (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16, 3507-3510.
58. Zimmer L., Delion-Vancassel S., Durand G., Guilloteau D., Bodard S., Besnard J. C. and Chalon S. (2000) Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J. Lipid Res. 41, 32-40.